Media

BioClin Therapeutics Presents FIERCE-21: Phase 1b/2 Study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory Metastatic Urothelial Carcinoma at the American Society of Clinical Oncology (ASCO). Chicago, IL.

Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology

Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy

Strongbridge Biopharma plc to Present at the Jefferies 2018 Global Healthcare Conference

Nordic Nanovector: Rainer Boehm, MD elected to Board of Directors

Nordic Nanovector ASA: Annual General Meeting held

Nordic Nanovector ASA – Results for the First Quarter 2018

BONESUPPORT to significantly expand its European sales organization

Alexion Offer For Wilson Therapeutics Accepted